These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 29262831)

  • 1. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis.
    Jung SY; Lee SH; Lee SY; Yang S; Noh H; Chung EK; Lee JI
    Crit Care; 2017 Dec; 21(1):319. PubMed ID: 29262831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia.
    Lee CH; Tang YF; Su LH; Chien CC; Liu JW
    Microb Drug Resist; 2008 Sep; 14(3):233-7. PubMed ID: 18707240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.
    Liu J; Shu Y; Zhu F; Feng B; Zhang Z; Liu L; Wang G
    J Glob Antimicrob Resist; 2021 Mar; 24():136-147. PubMed ID: 32889142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.
    Kengkla K; Kongpakwattana K; Saokaew S; Apisarnthanarak A; Chaiyakunapruk N
    J Antimicrob Chemother; 2018 Jan; 73(1):22-32. PubMed ID: 29069421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 21st-century challenge to neurocritical care: the rise of the superbug Acinetobacter baumannii. A meta-analysis of the role of intrathecal or intraventricular antimicrobial therapy in reduction of mortality.
    Mohammed N; Savardekar AR; Patra DP; Narayan V; Nanda A
    Neurosurg Focus; 2017 Nov; 43(5):E8. PubMed ID: 29088961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Zheng JY; Huang SS; Huang SH; Ye JJ
    J Microbiol Immunol Infect; 2020 Dec; 53(6):854-865. PubMed ID: 31607573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
    Betrosian AP; Frantzeskaki F; Xanthaki A; Douzinas EE
    J Infect; 2008 Jun; 56(6):432-6. PubMed ID: 18501431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review of Antimicrobial Resistance of Clinical Acinetobacter baumannii Isolates in Iran: An Update.
    Razavi Nikoo H; Ardebili A; Mardaneh J
    Microb Drug Resist; 2017 Sep; 23(6):744-756. PubMed ID: 28085571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features.
    Boral B; Unaldi Ö; Ergin A; Durmaz R; Eser ÖK;
    Ann Clin Microbiol Antimicrob; 2019 Jul; 18(1):19. PubMed ID: 31266519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant
    Oliva A; Garzoli S; De Angelis M; Marzuillo C; Vullo V; Mastroianni CM; Ragno R
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30832412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase.
    Wei W; Yang H; Liu Y; Ye Y; Li J
    J Chemother; 2016 Jun; 28(3):159-63. PubMed ID: 25978105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
    Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
    PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.
    Sakoulas G; Rose W; Berti A; Olson J; Munguia J; Nonejuie P; Sakoulas E; Rybak MJ; Pogliano J; Nizet V
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.
    Batirel A; Balkan II; Karabay O; Agalar C; Akalin S; Alici O; Alp E; Altay FA; Altin N; Arslan F; Aslan T; Bekiroglu N; Cesur S; Celik AD; Dogan M; Durdu B; Duygu F; Engin A; Engin DO; Gonen I; Guclu E; Guven T; Hatipoglu CA; Hosoglu S; Karahocagil MK; Kilic AU; Ormen B; Ozdemir D; Ozer S; Oztoprak N; Sezak N; Turhan V; Turker N; Yilmaz H
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1311-22. PubMed ID: 24532009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study.
    Assimakopoulos SF; Karamouzos V; Lefkaditi A; Sklavou C; Kolonitsiou F; Christofidou M; Fligou F; Gogos C; Marangos M
    Infez Med; 2019 Mar; 27(1):11-16. PubMed ID: 30882373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients.
    Tsioutis C; Kritsotakis EI; Karageorgos SA; Stratakou S; Psarologakis C; Kokkini S; Gikas A
    Int J Antimicrob Agents; 2016 Nov; 48(5):492-497. PubMed ID: 27542315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients].
    Pérez-Pedrero MJ; Sánchez-Casado M; Rodríguez-Villar S
    Med Intensiva; 2011 May; 35(4):226-31. PubMed ID: 21396739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?
    Kalin G; Alp E; Coskun R; Demiraslan H; Gündogan K; Doganay M
    J Infect Chemother; 2012 Dec; 18(6):872-7. PubMed ID: 22644081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii.
    Pournaras S; Poulou A; Dafopoulou K; Chabane YN; Kristo I; Makris D; Hardouin J; Cosette P; Tsakris A; Dé E
    Antimicrob Agents Chemother; 2014; 58(2):828-32. PubMed ID: 24247145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.